Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status
Approximately 2.5% of epithelial ovarian cancer patients (EOC) develop brain metastases (BM). 35% of these have a BRCA1/2 mutation
BM were diagnosed at a median of 31 months post diagnosis. Median survival from BM diagnosis to death was longer in BRCA patients. Brain metastases were the only evidence of disease at time of diagnosis in 48% of BRCA positive patients.
BRCA patients were more likely to have isolated BM, which may be a factor in their long survival. This supports the pursuit of aggressive treatment for BRCA EOC patients with BM.
No comments:
Post a Comment